Rosetta Genomics Ltd. (ROSG) Posts Q4, FY2010 Results

QualityStocks would like to highlight Rosetta Genomics (NASDAQ: ROSG), a leading developer of microRNA-based molecular diagnostics. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs.

In the company’s news yesterday,

Rosetta Genomics posted its financial results for the fourth quarter and 12 months ended December 31, 2010.

“2010 was a challenging but rewarding year for Rosetta Genomics, marked by achievements in a number of important areas. We streamlined our operations and cost structure, expanded our distribution into Greece, advanced miRview mets to commercial launch, fortified our patent portfolio and, importantly, regained U.S. rights to our first three commercial microRNA diagnostic tests. Moreover, we significantly expanded our scientific and clinical body of knowledge with multiple journal publications of data demonstrating the role of Rosetta’s microRNA technology as a potentially powerful biomarker and diagnostic tool,” Kenneth A. Berlin, president and CEO of Rosetta Genomics stated in the press release.

During the fourth quarter of 2010, Rosetta Genomics recorded revenues from continuing operations of $45,000, compared with $119,000 for the fourth quarter of 2010. The company’s net loss from continuing operations for the fourth quarter 2010 was $3.5 million, or $0.21 per ordinary share, compared with a net loss from continuing operations for the fourth quarter of 2009 of $4.1 million, or $0.29 per ordinary share.

Research and development expenses for the fourth quarter of 2010 declined to $1.2 million, compared with $1.7 million for the fourth quarter of 2009.

Marketing and business development expenses for the fourth quarter of 2010 were $1.6 million, slightly up from the $1.3 million reported for the fourth quarter of 2009.

General and administrative expenses for the fourth quarter of 2010 declined to $665,000, compared with $1.2 million for the fourth quarter of 2009.

The operating loss for the fourth quarter of 2010 was $3.6 million, including $329,000 of non-cash stock-compensation expense. This compares with an operating loss for the fourth quarter of 2009 of $4.1 million, including $615,000 of non-cash stock-compensation expense.

For full year 2010, the company reported revenues from continuing operations of $279,000, compared with $150,000 for the prior year period. Net loss from continuing operations for 2010 was $14.2 million, or $0.84 per ordinary share, compared with a net loss from continuing operations of $14.8 million, or $1.09 per ordinary share for 2009.

As of December 31, 2010 Rosetta Genomics reported $3.3 million in cash and cash equivalents, restricted cash, short-term bank deposit and marketable securities, compared with $10.3 million as of December 31, 2009. The year-end 2010 cash position does not include the $5.5 million in net proceeds from the concurrent private placement and registered direct offerings in February 2011.

The company also offered its expectations in the near future and gave an update on its progress in various markets.

“We are very excited about our new strategic direction for U.S. commercial operations. We are in the process of recruiting four to five independent sales representatives with an oncology focus to launch our microRNA-based diagnostic tests in several key oncology markets on the East coast. Our strategy is to focus our resources on commercializing our miRview mets tests as they address an important unmet medical need and largest, near-term market opportunity,” Berlin stated.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.